- Home
- CNTA
as 07-11-2025 3:34pm EST
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.
| Founded: | 2020 | Country: | United Kingdom |
| Employees: | N/A | City: | ALTRINCHAM, CHESHIRE |
| Market Cap: | 1.6B | IPO Year: | 2021 |
| Target Price: | $28.78 | AVG Volume (30 days): | 980.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.82 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.00 - $19.09 | Next Earning Date: | 08-12-2025 |
| Revenue: | $15,000,000 | Revenue Growth: | 118.88% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Centessa Pharmaceuticals plc (CNTA)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Weinhoff Gregory M | CNTA | Chief Business Officer | Jun 25 '25 | Sell | $13.86 | 10,000 | $138,642.00 | 122,279 | |
| SAHA SAURABH | CNTA | Chief Executive Officer | Jun 20 '25 | Sell | $12.63 | 55,000 | $694,826.00 | 221,017 | |
| Weinhoff Gregory M | CNTA | Chief Business Officer | May 27 '25 | Sell | $12.82 | 10,000 | $128,225.00 | 122,279 | |
| SAHA SAURABH | CNTA | Chief Executive Officer | May 20 '25 | Sell | $12.71 | 55,000 | $699,110.50 | 221,017 | |
| GOYAL ARJUN | CNTA | Director | May 15 '25 | Buy | $12.49 | 462,585 | $5,865,242.37 | 462,585 | |
| HUSSAIN IQBAL J | CNTA | General Counsel | May 1 '25 | Sell | $14.00 | 311 | $4,354.00 | 105,386 | |
| HUSSAIN IQBAL J | CNTA | General Counsel | Apr 25 '25 | Sell | $14.00 | 5,689 | $79,658.01 | 105,386 | |
| Weinhoff Gregory M | CNTA | Chief Business Officer | Apr 25 '25 | Sell | $13.61 | 11,742 | $159,856.76 | 122,279 | |
| SAHA SAURABH | CNTA | Chief Executive Officer | Apr 21 '25 | Sell | $12.36 | 55,000 | $681,576.18 | 221,017 |
Latest Centessa Pharmaceuticals plc News
CNTA Breaking Stock News: Dive into CNTA Ticker-Specific Updates for Smart Investing
Insider Monkey
18 days ago
Centessa Pharmaceuticals Receives FDA Clearance for New Drug ORX142, Initiates Phase 1 Study
Simply Wall St.
18 days ago
Centessa Pharmaceuticals plc's (NASDAQ:CNTA) Intrinsic Value Is Potentially 99% Above Its Share Price
MT Newswires
24 days ago
European Equities Traded in the US as American Depositary Receipts Edge Higher Wednesday
TipRanks
25 days ago
Centessa announces clearance of IND for ORX142
Zacks
a month ago
Centessa Pharmaceuticals (CNTA) Upgraded to Buy: What Does It Mean for the Stock?
MT Newswires
a month ago
Centessa Gets US FDA's Clearance to Start Phase 1 Trial of ORX142 for Neurological, Neurodegenerative Disorders
GlobeNewswire
a month ago
Centessa Pharmaceuticals Announces Clearance of Investigational New Drug Application (IND) for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist; Clinical Data in Acutely Sleep-Deprived Healthy Volunteers Planned for this Year
Zacks
a month ago
Wall Street Analysts Think Centessa Pharmaceuticals (CNTA) Could Surge 138.77%: Read This Before Placing a Bet
Compare CNTA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CNTA Centessa Pharmaceuticals plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.